PubRank

Bruno Paiva

Author PubWeight™ 27.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013 6.21
2 Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010 4.10
3 Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010 1.61
4 The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011 1.28
5 Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol 2014 1.15
6 CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012 1.14
7 Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 2012 1.10
8 Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2012 1.04
9 Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 2011 1.03
10 CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2010 0.96
11 GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 2014 0.96
12 Deficient spindle assembly checkpoint in multiple myeloma. PLoS One 2011 0.94
13 Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica 2012 0.93
14 Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2013 0.85
15 Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2010 0.82
16 Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica 2012 0.82
17 New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book 2013 0.81
18 Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol 2014 0.77
19 Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114. Haematologica 2013 0.77
20 Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. Br J Haematol 2013 0.76
21 Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry. Clin Lymphoma Myeloma Leuk 2011 0.75
22 Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Mol Cancer Ther 2014 0.75